Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Brief description of study
The purpose of this study is to determine if accelerated BEP will be more effective but not significantly more toxic than standard BEP.
Detailed description of study
The purpose of this study is to determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is superior to standard BEP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Germ Cell Tumor
-
Age: 11 years - 45 years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Age greater than/equal to 11 years and less than or equal to 45 years on the date of randomisation
- Histologically or cytologically confirmed germ cell tumour (non-seminoma or seminoma); or exceptionally raised tumour markers (AFP greater than/equal to 1000ng/mL and/or HCG greater than/equal to 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently.
For a full list of participation criteria, please visit clinicaltrials.gov.
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or